Login / Signup
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.
Hendrik Schulze-Koops
Klaus Krueger
Inka Vallbracht
Rebecca Hasseli
Alla Skapenko
Published in:
Annals of the rheumatic diseases (2020)
Keyphrases
</>
coronavirus disease
sars cov
diffuse large b cell lymphoma
early onset
oxidative stress
hodgkin lymphoma
chronic lymphocytic leukemia
respiratory syndrome coronavirus
drug induced